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A B S T R A C T
Background
Early thrombolysis for individuals experiencing a myocardial infarction is associated with better mortality and morbidity outcomes.
While traditionally thrombolysis is given in hospital, pre-hospital thrombolysis is proposed as an effective intervention to save time
and reduce mortality and morbidity in individuals with ST-elevation myocardial infarction (STEMI). Despite some evidence that pre-
hospital thrombolysis may be delivered safely, there is a paucity of controlled trial data to indicate whether the timing of delivery can
be effective in reducing key clinical outcomes.
Objectives
To assess the morbidity and mortality of pre-hospital versus in-hospital thrombolysis for STEMI.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (OVID), EMBASE (OVID), two citation
indexes on Web of Science (Thomson Reuters) and Cumulative Index to Nursing and Allied Health Literature (CINAHL) for
randomised controlled trials and grey literature published up to June 2014. We also searched the reference lists of articles identified,
clinical trial registries and unpublished thesis sources. We did not contact pharmaceutical companies for any relevant published or
unpublished articles. We applied no language, date or publication restrictions. The Cochrane Heart Group conducted the primary
electronic search.
Selection criteria
We included randomised controlled trials of pre-hospital versus in-hospital thrombolysis in adults with ST-elevation myocardial
infarction diagnosed by a healthcare provider.
Data collection and analysis
Two authors independently screened eligible studies for inclusion and carried out data extraction and ’Risk of bias’ assessments, resolving
any disagreement by consulting a third author. We contacted authors of potentially suitable studies if we required missing or additional
information. We collected efficacy and adverse effect data from the trials.
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Main results
We included three trials involving 538 participants. We found low quality of evidence indicating uncertainty whether pre-hopsital
thrombolysis reduces all-cause mortality in individuals with STEMI compared to in-hospital thrombolysis (risk ratio 0.73, 95%
confidence interval 0.37 to 1.41). We found high-quality evidence (two trials, 438 participants) that pre-hospital thrombolysis reduced
the time to receipt of thrombolytic treatment compared with in-hospital thrombolysis. For adverse events, we found moderate-quality
evidence that the occurrence of bleeding events was similar between participants receiving in-hospital or pre-hospital thrombolysis (two
trials, 438 participants), and low-quality evidence that the occurrence of ventricular fibrillation (two trials, 178 participants), stroke
(one trial, 78 participants) and allergic reactions (one trial, 100 participants) was also similar between participants receiving in-hospital
or pre-hospital thrombolysis. We considered the included studies to have an overall unclear/high risk of bias.
Authors’ conclusions
Pre-hospital thrombolysis reduces time to treatment, based on studies conducted in higher income countries. In settings where it
can be safely and correctly administered by trained staff, pre-hospital thrombolysis may be an appropriate intervention. Pre-hospital
thrombolysis has the potential to reduce the burden of STEMI in lower- and middle-income countries, especially in individuals who
have limited access to in-hospital thrombolysis or percutaneous coronary interventions. We found no randomised controlled trials
evaluating the efficacy of pre-hospital thrombolysis for STEMI in lower- and middle-income countries. Large high-quality multicentre
randomised controlled trials implemented in resource-constrained countries will provide additional evidence for the efficacy and safety
of this intervention. Local policy makers should consider their local health infrastructure and population distribution needs. These
considerations should be taken into account when developing clinical guidelines for pre-hospital thrombolysis.
P L A I N L A N G U A G E S U M M A R Y
Delivering clot-busting therapy before reaching hospital or in hospital to help people who are having heart attacks
Heart disease is the most common cause of death worldwide according to the World Health Organization. A heart attack can either be
treated with a drug called a thrombolytic (clot buster) or with surgery. The earlier a thrombolytic is given, the less likely the individual
is to die or have disabilities. Usually, thrombolysis is given in a hospital; however, the administration of this therapy before hospital, by
paramedics, may be an effective intervention that may save time and reduce death and disability in people with heart attacks.
The aim of this review was to compare the effect of pre-hospital and in-hospital administration of thrombolytic therapy on all-cause
death and disability in individuals having a heart attack. We carried out a comprehensive search for all trials that have investigated
this outcome. Two authors worked independently to ensure we found all of the trials and obtained the relevant information from
them. Overall, we found three trials with 538 participants which could be included in this review. We found low-quality evidence
indicating uncertainty whether the numbers of people dying were different when therapy was given before hospital compared to in
hospital (3 trials). We found high-quality evidence that giving therapy before hospital reduced the time taken for an individual to
receive thrombolytic therapy by more than 30 minutes (two studies) and generally low-quality evidence that side effects, such as allergic
reactions and bleeding, were similar whether therapy was given pre-hospital or in hospital. The main limitations of the evidence were
the unclear/high risk of bias in the studies and the low numbers of people recruited.
We conclude that clot-busting therapy given before arriving at a hospital reduces the time taken for an individual to receive thrombolytic
treatment. The limitations of the evidence we have found should be considered carefully, especially in settings where thrombolysis can
be safely and correctly administered by trained staff. We found that there were no trials evaluating pre-hospital thrombolytic therapy in
poorer countries, and therefore further research in such settings will provide more information to advise on whether giving this therapy
for heart attacks is safe and effective.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction
Participants or population: participants with ST-elevation myocardial infarction
Settings: USA, France and Germany
Intervention: Pre-hospital versus in-hospital thrombolysis
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Pre-hospital versus in-
hospital thrombolysis
All-cause hospital mor-
tality
Follow up: 30 days1
73 per 1000 53 per 1000
(27 to 103)
RR 0.73
(0.37 to 1.41)
538
(3 studies)
⊕⊕©©
low2,3
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Follow up ranged from 15 days to 1 month
2 Downgraded by 1 level for risk of bias due to poor reporting of random sequence generation, allocation concealment (not described
and concealment broken) and inadequate outcome reporting in Castaigne 1989
3 Downgraded by 1 level for imprecision as CI includes appreciable benefit and appreciable harm.
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B A C K G R O U N D
Description of the condition
The World Health Organization (WHO) reports that cardiovas-
cular disease is the leading cause of death worldwide, with more
than 80% of these deaths occurring in lower- and middle-income
countries (LMICs) (Mackay 2004; WHO 2011). Cardiovascular
disease is responsible for more than 10% of disability-adjusted life-
years lost in LMICs and for more than 18% of disability-adjusted
life-years lost in high-income countries (HICs) (Mackay 2004).
ST-segment elevation myocardial infarction (STEMI) falls under
the umbrella classification of acute coronary syndromes (ACS),
which also include non-ST-segment elevation myocardial infarc-
tion (NSTEMI) and unstable angina (Ruff 2011). A STEMI is the
development of myocardial necrosis secondary to the interruption
of the blood supply to an area of themyocardium identified by the
presence of ST segment elevation on electrocardiography or the
elevation of cardiac markers, or both. In the United States there
has been a striking evolution in the epidemiology of ACS since
the 1990s, with a steady decline in the incidence of STEMIs and
a reciprocal incline in the incidence of NSTEMIs, as reported by
Rogers 2008. In LMICs there is an increasing trend in ischaemic
heart disease mortality (Mensah 2008) as these countries move
through an epidemiological transition of increasing incidence and
prevalence of cardiovascular disease (Gersh 2010). Acute myocar-
dial infarction is defined as cardiac muscle death owing to pro-
longed lack of oxygenation (Thygesen 2007) caused by an abrupt
reduction in coronary blood flow to part of the heart (Beers 2006).
Symptoms of acute myocardial infarctionmay bemore severe than
those associated with angina and usually persist for longer (e.g.
more than 15 to 20 minutes). Classic symptoms include chest dis-
comfort or pain but can include other symptoms such as short-
ness of breath, nausea, sweating, dizziness and vomiting (Goodacre
2002; Goodacre 2003). Health costs relating to people suffering
from acute myocardial infarction are diverse, with economic im-
plications to the individual, family, healthcare system and country
(IOM 2010).
Description of the intervention
STEMIs can be treated effectively using percutaneous coronary
interventions (PCIs) or thrombolytic agents, or both (Bonnefoy
2009; Weaver 1993). Thrombolytic agents are enzymes that cause
coronary thrombus dissolution through a cascade of effects to de-
grade fibrin thrombi and fibrinogen (SAMF 2010). These agents
can be administered either in the pre-hospital setting or, tradition-
ally, in a hospital setting, and are most effective if given in the first
few minutes to hours after onset of a STEMI (Beers 2006; Rawles
2003; Weaver 1993). Various thrombolytic agents are available,
all with similar biological effects, efficacy and administration re-
quirements. These include, but are not limited to, the following
agents:
• streptokinase, 1.5 million units intravenously (IV) over 30
to 60 minutes;
• alteplase, 15 mg IV 0.75 mg/kg over 30 minutes followed
by 0.5 mg/kg IV over 60 minutes;
• reteplase, 10 U + 10 U IV given 30 minutes apart;
• tenecteplase, single IV injection (weight dependent) (Van
de Werf 2008).
A thrombolytic agent is administered either by infusion or as a sin-
gle bolus dose. This distinction is important to note as bolus doses
are generally easier to administer, require less resources (e.g. an in-
fusionpump) and expertise. Treatment of STEMIs is aimed at early
diagnosis and risk stratification, with relief of pain, breathlessness
and anxiety coupled with immediate coronary reperfusion either
with a pharmacological or mechanical intervention depending on
availability and on each individual’s context (O’Connor 2010).
The standard of care includes anti-ischaemic therapy (oxygen, ni-
troglycerin, opioids and beta-blockers), antiplatelet therapy (As-
pirin, clopidogrel) (Fox 2004; ISIS-2 1988), antithrombin ther-
apies (heparin and low-molecular-weight heparins) (Armstrong
2006) and reperfusion strategies (O’Connor 2010; Van de Werf
2008).
How the intervention might work
Effective thrombolysis for individuals with STEMI is extremely
time sensitive (Sayah 2008). The earlier a thrombolytic agent is
initiated the better, with greatest benefit occurring within three
hours from symptom onset (Bonnefoy 2009). The goal is to ini-
tiate thrombolysis within 30 to 60 minutes after symptom onset
(Antman 2008). Despite this goal, achieving this in practice is
challenging (Barbagelata 2007). Pre-hospital initiation of throm-
bolysis has been reported to improve time to thrombolysis and re-
duce mortality compared with in-hospital thrombolysis (Antman
2008 (narrative); Björklund 2006 (cohort study); Bonnefoy 2009;
Brouwer 1996; Rawles 2003 (trials); Curtis 2006 (descriptive);
Morrison 2000 (review)).
Why it is important to do this review
Early thrombolysis has been associated with better mortality and
morbidity outcomes (Bonnefoy 2009). Pre-hospital thromboly-
sis can provide improved time to thrombolysis (Björklund 2006)
and a potential reduction in mortality and morbidity compared
with in-hospital treatment (Rawles 2003). A previous systematic
review byMorrison 2000 found that pre-hospital thrombolysis for
acute myocardial infarction significantly decreased all-cause hos-
pital mortality based on a meta-analysis of six randomised con-
trolled trials (RCTs). This review incorporated any new evidence
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and utilised the GRADE assessment, together with Cochrane
Heart Group methodology. It added to current knowledge of pre-
hospital thrombolysis by considering system and infrastructure
needs for the successful implementation of the models of care and
ascertained gaps in current research evidence. The results of this
review may guide policy makers and other healthcare stakeholders
to invest in the appropriate treatment strategy and health system/
service requirements for individuals with STEMI needing throm-
bolysis, especially in LMICs where other treatment options for
STEMI are scarce or not available. This review has important im-
plications for areas where primary angioplasty is unavailable or
where pre-hospital transport times are long, such as rural areas -
specifically in LMICs.
O B J E C T I V E S
To assess the morbidity and mortality of pre-hospital versus in-
hospital thrombolysis for STEMI.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs excluding cross-over trials.
Types of participants
Adults (16 years and older) with STEMI diagnosed by a medical
healthcare provider in either the pre-hospital or in-hospital setting.
Diagnosis of STEMI will be defined according to the included
studies’ criteria for STEMI but should include at least two of the
following three positive indicators: the individual’s history and
symptoms, electrocardiogram (ECG) findings and biochemical
cardiac markers (cardiac makers are not mandatory for diagnosis,
but may be used in certain pre-hospital settings).
Types of interventions
Any thrombolytic agent used to treat STEMI in pre-hospital and
in-hospital settings.
Types of outcome measures
Primary outcomes
All-cause hospital mortality at one month (short term) and one
year (mid term).
Secondary outcomes
1. Time to thrombolytic treatment, measured from symptom
onset or first medical contact, or both (or as described by study
authors) to the administration of a thrombolytic agent
2. Adverse effects. An adverse event is defined as an event for
which a causal relationship between the intervention and the
event is a reasonable possibility (e.g. ventricular fibrillation,
pulseless ventricular tachycardia, cardiogenic shock,
inappropriate use of thrombolytics, hypotension, bradycardia,
re-infarction, bleeding, or fatal and non-fatal stroke)
3. Acute myocardial infarction functional outcomes including:
◦ ejection fraction, measured using an echocardiogram;
◦ classification of heart failure (New York Heart
Association functional classification system);
◦ time to discharge or days in hospital, measured from
admission to discharge in days
Search methods for identification of studies
Electronic searches
In June 2014, we conducted comprehensive electronic searches
for RCTs using the following key search terms - thrombolysis,
thrombolysis therapy, myocardial infarction, and pre-hospital -
and using the Cochrane sensitivity-precision maximising RCT fil-
ter (Lefebvre 2011), adapted for use with the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL, issue 5 of 12, September 2014, searched 5 June
2014, results: 1491);
• MEDLINE (OVID, 1946 to May Week 4 2014, searched
10 June 2014, results: 1178);
• EMBASE Classic + EMBASE (OVID, 1947 to 5 June
2014, searched 5 June 2014, results: 1196);
• Science Citation Index Expanded (SCI-EXPANDED, 1970
to 5 June 2014) and Conference Proceedings Citation Index-
Science (CPCI-S, 1990 to 5 June 2014) on Web of Science
(Thomson Reuters) searched 5 June 2014; results: 2489;
• CINAHL Plus with Full Text (EBSCO, 1936 to May 2014,
searched 5 June 2014, results: 117).
We added no language or publication restrictions to the search
strategies. The search strategies used can be found in Appendix 1.
In developing the search strategy we were assisted by the Cochrane
Heart Review Group’s Trials Search Co-ordinator who conducted
the main search.
Searching other resources
We searched grey literature, such as unpublished thesis sources, and
the following additional databases: ProQuest Dissertations, Index
to theses in Great Britain and Ireland, and DissOnline.We carried
out nohandsearching and contactednopharmaceutical companies
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in order to identify additional studies due to operational time
restraints.
We searched the reference lists of included studies and con-
tacted the primary authors of included studies to identify addi-
tional relevant studies. We searched the following clinical trial reg-
isters: ClinicalTrials.gov (www.clinicaltrials.gov/), International
Standard Randomised Controlled Trial Register (www.controlled-
trials.com/isrctn/) and the WHO International Clinical Trials
Registry Platform (apps.who.int/trialsearch/).
Data collection and analysis
Selection of studies
We merged the results of the search using reference management
software and removed duplicate records. Two review authors (MM
and AL) independently examined titles and abstracts to remove
obviously irrelevant reports and retrieved the full text of potentially
relevant reports. They linked multiple reports of the same study
and independently examined full-text reports for compliance with
eligibility criteria using a study eligibility form. MM and AL re-
solved any disagreements regarding study inclusion or exclusion
with the assistance of the other author, TK. Neither author was
blinded to the names of the study authors, institutions, journal
of publication nor results, as this practice has uncertain benefit
in protecting against bias (Higgins 2011). We created a PRISMA
flow diagram (Moher 2009) to show the process of inclusion and
exclusion of RCTs; potentially eligible studies that were excluded
are noted in the ’Excluded studies’ section.
Data extraction and management
Two review authors (MM and AL) independently extracted data
from the studies using a data extraction form. We collected the
following information:
• study source (name of person extracting data, study ID,
report ID, review author, citation and contact details);
• eligibility (confirmation of eligibility for review as per
protocol, reason for exclusion);
• methods (study aims, study design, total study duration,
unit of allocation, all information required for the ’Risk of bias’
tool, ethics approval);
• participants and setting (age, recruitment method, inclusion
and exclusion criteria, baseline imbalances, informed consent
obtained, number of participants randomised, time of first
symptom onset, rural or urban setting, developing or developed
country setting, subgroups measured, subgroups reported);
• interventions (group name, number randomised to group,
type of medication administered, method of administration,
time of medication administration, place of administration,
number and explanation for any dropouts, duration of follow
up, economic variables);
• outcome measures coupled with results (outcome
definition/name, person measuring or reporting, all-cause
hospital mortality at 30 days and one year or longer where
available, time to thrombolytic treatment, adverse effects,
STEMI functional outcomes, comorbidities);
• results (continuous variables of outcome data such as
measures of variability, dichotomous data such as total number
of events in each arm and numbers of participants), additional
notes (key conclusions of study, correspondence with authors
needed, clarification of queries, ethics or stated conflicts of
interest, duplicate publication, translation required);
• applicability (populations excluded, disadvantaged groups,
applicability to developing countries).
We collated data from multiple reports of the same study into one
data extraction form. MM collated and entered all data into Re-
view Manager 5 (RevMan 2011). We resolved any disagreements
by consensus.
Assessment of risk of bias in included studies
Two review authors (MM and AL) independently assessed the risk
of bias of included studies using the Cochrane ’Risk of bias’ as-
sessment tool (six domains) (Higgins 2011), stating whether the
risk of bias was low, high or unclear. The two authors indepen-
dently pooled the results and discussed any differences with a third
author (TK). We addressed the following bias domains: sequence
generation, allocation concealment, blinding (blinding of partic-
ipant and personnel, blinding of outcome assessors), incomplete
outcome data, selective outcome reporting and other risks of bias.
The review authors followed the criteria given in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)
for assessing bias. We extracted information based on the pub-
lished data and contacted the authors whenever descriptions were
missing or unclear.
Measures of treatment effect
Dichotomous data
Dichotomous outcomes, such as all-cause hospital mortality, were
represented as risk ratios (RR) with 95% confidence intervals
(CIs). Adverse effect data were measured as proportions or rates,
respectively, depending on the study data.
Continuous data
Continuous effect measures included the time from symptom on-
set to thrombolysis,measured as themeandifference (MD)or stan-
dardised MD between individuals receiving thrombolytic therapy
in a pre-hospital or an in-hospital setting. Time to discharge, num-
ber of days in hospital and ejection fraction weremeasured asMDs
or standardised MDs between groups.
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Unit of analysis issues
OnlyRCTs were included. The authors identified no cluster RCTs
ormulti-armRCTs.Hence, the unit of analysiswas at an individual
level.
Dealing with missing data
We asked the authors of one RCT (the European Myocardial In-
farction Project (EMIP)) to provide missing data so that the study
could potentially be included in the review. Unfortunately they
were unable to provide any data and the trial was excluded from
the study. We performed no imputing of missing data.
Assessment of heterogeneity
We performed a visual inspection of the forest plot for heterogene-
ity. Heterogeneity was assessed using the Chi2 test, with a P value
< 0.1 considered indicative of significant heterogeneity, and the
I2 statistic. As there was reasonable clinical and methodological
similarity between trials, we were able to carry out a meta-analysis.
We sought possible reasons for any substantial heterogeneity.
Assessment of reporting biases
The use of a funnel plot to explore possible reporting biases was
precluded due to the limited number of included studies (< 10).
Data synthesis
As the trials were clinically and methodologically similar, we un-
dertook a meta-analysis. We used a fixed-effect meta-analysis if
studies were estimating the same treatment effect (no statisti-
cal heterogeneity) and a random-effects meta-analysis if studies
showed substantial statistical heterogeneity.We usedRevMan soft-
ware to perform themeta-analysis. If we performed ameta-analysis
in the presence of high levels of heterogeneity, we sought possible
explanations for this heterogeneity.
Subgroup analysis and investigation of heterogeneity
We predefined several possible subgroups for meta-analysis:
• practitioner type: paramedic (basic versus advanced) versus
physician (emergency versus cardiologist) thrombolytic
administration on mortality outcome;
• HIC versus LMIC settings;
• rural versus urban settings;
• remote telemetry with consultant communication versus
independent paramedic thrombolytic administration;
• automated versus manual ECG interpretation;
• different types of thrombolytic medication administered
compared for mortality and adverse effects;
• anatomical location of STEMI;
• mobile intensive care units compared with primary
response;
• adverse effects of pre-hospital thrombolytic agents as
administered by paramedics versus physicians.
However, we did not perform any subgroup analyses due to the
limited number of included studies. The Cochrane Handbook for
Systematic Reviews of Interventions recommends a minimum of 10
studies.
Sensitivity analysis
We performed sensitivity analyses in order to explore the influence
of the following factors on effect size:
• fixed-effect model versus a random-effects model meta-
analyses;
• exclusion of trials with a high risk of bias.
R E S U L T S
Description of studies
Results of the search
The electronic database searches identified 6471 titles for potential
inclusion. After the removal of duplications, 4111 titles remained
of which 4027 titles were found not to be relevant. We retrieved
full-text articles for the remaining 84 titles which two authors
independently screened for eligibility. We included three studies,
reported in six papers, met the eligibility criteria. The trial registry
searches revealed 146 potentially eligible studies of which all we
excluded (Figure 1). Ten trials were translated with the help of the
Cochrane Heart Group.
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Figure 1. Study flow diagram.
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Included studies
See: Characteristics of included studies
We identified three RCTs (538 participants), conducted in France,
USA and Germany, which examined the efficacy of pre-hospital
versus in-hospital thrombolysis for STEMI. Castaigne 1989 used
30 U anisoylated plasminogen streptokinase activator complex
(APSAC) whereas Schofer 1990 used urokinase (2 million U IV)
andWeaver 1993 used alteplase 100 mg as the thrombolytic agent
in both the intervention and control arms. In Castaigne 1989 and
Schofer 1990 physicians inmobile care units administered the pre-
hospital thrombolytic agents whereas in Weaver 1993 paramedics
administered the thrombolytic. The primary outcomes were sim-
ilar across all three trials and included mortality, time intervals,
angiographic data, ejection fraction and complications.
Castaigne 1989 was a two phase study conducted in the Val de
Marne district close to Paris, France. The first phase comprised a
simulation pilot study and an education study; the latter evalu-
ated anaesthesiologists’ hypothetical decision to correctly throm-
bolyse individuals with chest pain possibly due to ACS in mobile
care units. A total of 294 participants were reviewed over 1 year.
The second phase of the study was a RCT comparing pre-hospital
versus in-hospital thrombolysis conducted over 2 years using 30
U APSAC injected over more than four minutes. The researchers
screened 320 individuals with STEMI, and 100 were included in
the trial. The intervention in both treatment groups was adminis-
tered by physicians (including that inmobile care units). Themain
outcome for phase one of the study was diagnostic accuracy; that
for the second phase was the delay between at-home and in-hos-
pital injection for participants having received placebo at home.
Schofer 1990 was an RCT conducted in Germany within the
mobile care unit systems of AK Altona, Stadtische Kliniken Kiel
and Darmstadt. The pre-hospital group (40 participants) received
urokinase (2 million U IV) at home and placebo at hospital
whereas the in-hospital group (38 participants) received placebo at
home and urokinase (2million U IV) at hospital, both followed by
1000U/hour of heparin at hospital. Urokinase was dilutedwith 20
mL of injectable water. The mobile care units were staffed with a
physician and two emergency medical technicians. The following
study endpoints were reported: time intervals, angiographic data
and creatine kinase levels, stress test before discharge and compli-
cations.
Weaver 1993 was an RCT of pre-hospital versus in-hospital initi-
ated thrombolytic therapy conducted in Seattle metropolitan area
and the surrounding King County, in the USA. The trial ran from
November 1988 to December 1991, and involved 19 hospitals
and all paramedical systems in the Metropolitan area. The pre-
hospital-initiated group received Aspirin 325 mg and alteplase
100 mg at home and no placebo at hospital whereas the hospi-
tal-initiated group received no placebo at home and Aspirin 325
mg and alteplase 100 mg at hospital. A total of 360 participants
were included in the study, 175 and 185 in the pre-hospital and
in-hospital treatment arms, respectively. Pre-hospital thromboly-
sis was performed by paramedics (emergency care professionals)
with physician guidance. Study endpoints included diagnostic ac-
curacy of STEMI, time to treatment, pre-hospital and in-hospital
complications, ejection fraction and infarct size.
Excluded studies
See: Characteristics of excluded studies
Risk of bias in included studies
See: ’Risk of bias’ summary: review authors’ judgements about
each ’Risk of bias’ item for each included study (Figure 2).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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See: ’Risk of bias’ graph: review authors’ judgements about each
’Risk of bias’ item presented as percentages across all included
studies (Figure 3).
Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Schofer 1990, Weaver 1993 and Castaigne 1989 provided no de-
scription of random sequence generation; as a result we considered
the risk of bias to be unclear. We judged the risk of bias for alloca-
tion concealment in Castaigne 1989 to be high as the allocation
code was broken. We considered Schofer 1990 and Weaver 1993
to have a low risk of bias for allocation concealment.
Blinding
We considered the risk of bias for the blinding of participants and
personnel, as well as for outcome assessment (detection bias), in
Castaigne 1989 to be high. The authors of this study state that the
mobile care unit physicians were blinded. However, the blinding
is not described and the code could be broken if the physician
thought it necessary. Upon arrival at hospital the code was broken
as all the other physicians and assessors would have knowledge
of the treatment received. In Schofer 1990, we judged the risk
of bias due to the blinding of participants and personnel to be
low as numbered paired ampoules containing either placebo or
thrombolysis were used. For outcome assessment we judged the
risk to be unclear as no description was provided. We considered
the risk of bias due to blinding of participants and personnel in
Weaver 1993 to be high as alteplase was administered in an open
manner; we judged the risk of bias for outcome assessment to be
low as the groups were unknown to the assessor.
Incomplete outcome data
We judged the risk of bias for incomplete outcome data to be
high in Castaigne 1989 and Schofer 1990, and unclear in Weaver
1993. Participants in Castaigne 1989 were not assessed according
to intention-to-treat analysis and some outcome data were not re-
ported. In Schofer 1990 some data were excluded from analysis
and some were missing. Weaver 1993 did not report whether par-
ticipants were lost to follow up or withdrawn from participation.
Selective reporting
We judged Castaigne 1989 and Schofer 1990 to have a low risk of
bias for selective reporting. We considered Weaver 1993 to have a
high risk as some prespecified complications were not reported in
the intervention group.
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Other potential sources of bias
Schofer 1990 andWeaver 1993 had no indications of other sources
of bias and as a result we judged this risk to be low. We judged
Castaigne 1989 tohave anunclear risk as the report did not include
a table of baseline characteristics.
Effects of interventions
See: Summary of findings for themain comparison Pre-hospital
versus in-hospital thrombolysis for ST-elevation myocardial
infarction; Summary of findings 2 Pre-hospital versus in-hospital
thrombolysis for ST-elevation myocardial infarction
Primary outcome
Mortality data were available for all three included RCTs. How-
ever, none of the studies presented the mortality data over the pre-
specified time periods (one month and one year); hence, no time
period was used and we report the general all-cause mortality rate.
There is lowquality evidence indicatinguncertainty aboutwhether
pre-hospital compared to in-hospital thrombolysis reduces mor-
tality (Summary of findings for the main comparison) (RR 0.73,
95% CI 0.37 to 1.41, three RCTs; 538 participants) (Analysis
1.1). There was no heterogeneity between studies (Chi2 = 0.29; P
value = 0.86; I2 = 0%) and we therefore used a fixed-effect model
for meta-analysis (Analysis 1.1). Further research is likely to have
an important impact on our confidence in the estimate of effect
and is likely to change the estimate. It should be noted that the
meta-analysis included only 538 participants and thus one should
interpret these results with caution. We rated the studies as having
an overall unclear/high risk of bias (Figure 3).
A sensitivity analysis excluding the trial with a high risk of bias
(Castaigne 1989) also found no significant difference between the
pre-hospital and in-hospital thrombolysis groups (Analysis 3.1).
Excluding Castaigne 1989, however, resulted in a shift of the
pooled effect measure towards a stronger protective effect of pre-
hospital thrombolysis compared with the non-sensitivity analysis
(RR 0.68 compared with 0.73), although the difference between
groups remained non-significant.
Secondary outcomes
Time to thrombolysis
Schofer 1990 and Weaver 1993 presented data on the time from
the onset of symptoms to thrombolysis. There was high-quality
evidence (Summary of findings 2) that pre-hospital thromboly-
sis reduced the mean time to thrombolysis by 38 minutes (MD
-37.95 minutes. 95% CI -61.12 to -14.77, two RCTs; 438 par-
ticipants, Analysis 2.1). We found substantial heterogeneity (Chi
2 = 3.53; P value = 0.06; I2 = 72%) and we therefore conducted
a random-effects meta-analysis. Heterogeneity was not thought
to be sufficiently significant to forgo meta-analysis as a visual in-
spection revealed overlapping CIs and point estimates in a similar
direction. We rated these two studies as having an overall low risk
of bias (Figure 2).
Acute myocardial infarction functional outcomes
All three included RCTs reported mean percentage ejection frac-
tion. However, Castaigne 1989 presented the mean percentage
ejection fraction for pre-hospital thrombolysis (56.7%) and in-
hospital thrombolysis (53.4%) without providing the standard de-
viations for the measurements. We therefore conducted a meta-
analysis including Schofer 1990 andWeaver 1993 only.We found
low-quality evidence (Summary of findings 2) that there may be
no difference between the ejection fraction in pre-hospital versus
in-hospital thrombolysis (MD -1.18, 95% CI -3.50 to 1.13, two
RCTs; 416 participants, Analysis 2.2). As we found no hetero-
geneity (Chi2 = 0.16; P value = 0.69; I2 = 0%), we therefore used
a fixed-effect model for meta-analysis. The low-quality data indi-
cate that further research is likely to have an important impact on
our confidence in the estimate of effect and is likely to change the
estimate. We rated these two studies as having an overall low risk
of bias (Figure 2).
None of the included RCTs reported data on the acute myocar-
dial infarction functional outcomes, classification of heart failure
(New York Heart Association functional classification system) and
time to discharge or days in hospital, measured from admission to
discharge (proposed secondary outcomes).
Adverse effects
Four adverse effects were prioritised as clinically important and
incorporated in the GRADE assessment: ventricular fibrillation,
stroke, allergic reaction and bleeding.
There was low-quality evidence that there may be no difference
in the occurrence of ventricular fibrillation (two RCTs), stroke
(one RCT) or allergic reactions (one RCT) between groups. There
was moderate-quality evidence that was no difference in bleeding
complications between groups (two RCTs, Summary of findings
2). We downgraded the evidence due to imprecision as the confi-
dence interval included appreciable harm and appreciable benefit
(Analysis 2.3).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction
Participant or population: participants with ST-elevation myocardial infarction
Settings: USA, France and Germany
Intervention: Pre-hospital versus in-hospital thrombolysis
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Pre-hospital versus in-
hospital thrombolysis
Time to thrombolytic
treatment [minutes]
The mean time to throm-
bolytic treatment [min-
utes] in the intervention
groups was
37.95 lower
(61.12 to 14.77 lower)
438
(2 studies)
⊕⊕⊕⊕
high1
Acute myocardial infarc-
tion functional outcomes
- ejection fraction [per-
centage]
The mean acute myocar-
dial infarction functional
outcomes - ejection frac-
tion [percentage] in the
intervention groups was
1.18 lower
(3.50 lower to 1.13
higher)
416
(2 studies)
⊕⊕©©
low2,3
Adverse effects - ven-
tricular Fribrillation
25 per 1000 67 per 1000
(17 to 268)
RR 2.73
(0.68 to 10.86)
178
(2 studies)
⊕⊕©©
low4
Adverse effects - bleed-
ing complications
58 per 1000 51 per 1000
(24 to 112)
RR 0.88
(0.41 to 1.92)
438
(2 studies)
⊕⊕⊕©
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Adverse effects - allergic
reaction
0 per 1000 0 per 1000
(0 to 0)
RR 0
(0.19 to 77.03)
100
(1 study)
⊕⊕©©
low4
Adverse effects - Stroke 11 per 1000 23 per 1000
(4 to 123)
RR 2.11
(0.39 to 11.4)
360
(1 study)
⊕⊕©©
low4
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Methodological quality (e.g. no blinding in Castaigne 1989) not likely to effect this outcome, therefore not downgraded due to risk of
bias
2 Downgraded by 1 level for risk of bias. Schofer 1990 had participants lost to follow up for this outcome (n = 17). Extent of non-
differential or differential loss to follow up unknown
3 Downgraded for imprecision, CI includes appreciable benefit and appreciable harm
4 Downgraded by 2 levels for imprecision. Low event rate and wide CI
5 Downgraded by 1 level for imprecision
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D I S C U S S I O N
Summary of main results
There is lowquality evidence indicatinguncertainty aboutwhether
pre-hospital compared to in-hospital thrombolysis reducesmortal-
ity . Additional datamay change this finding (Summary of findings
for the main comparison).We rated the included studies as having
an overall unclear/high risk of bias (Figure 3).
We found high-quality evidence that the time to thrombolysis in
those who were thrombolysed pre-hospital compared with those
thrombolysed in hospital was statistically significantly reduced by
38minutes.We rated the studies included in this analysis as having
an overall low risk of bias (Figure 3).
We found low-quality evidence that there may be no difference
in acute myocardial infarction functional outcomes (ejection frac-
tion) between pre-hospital and in-hospital thrombolysis. We rated
the relevant studies as having an overall low risk of bias (Figure 3).
There was low-quality evidence that there may be no difference in
adverse effects between pre-hospital and in-hospital thrombolysis
(Summary of findings 2). We rated the relevant studies as having
an overall low risk of bias (Figure 3).
Overall completeness and applicability of
evidence
We were able to include only three relatively small trials in this
review and this influences the external validity of our findings. We
were unable to obtain requested data from a potentially eligible
study and therefore have excluded it (EMIP). The excluded study
could have contributed to the power of the meta-analysis to detect
a difference between groups for the primary outcome. None of the
included studies presented data on heart failure classification and
days in hospital or time to discharge. The results of this review are
applicable to HICs but less so to LMICs, as all the included trials
were conducted in developed country settings. We were unable to
perform subgroup analyses due to the limited number of included
studies.
The findings of this review have strong external validity when gen-
eralised to HICs; however, LMICs need to take into considera-
tion their unique health and emergency medical care systems. Lo-
cal policy makers and clinical directors should consider their lo-
cal health infrastructure and population distribution needs (rural
compared with urban), emergency care systems and availability
of the intervention compared with surgical alternatives (e.g. avail-
ability of PCI). These considerations should be taken into account
when developing clinical guidelines for pre-hospital thrombolysis.
Quality of the evidence
We used GRADE methodology to explore the quality of the ev-
idence. The primary outcome, mortality, was supported by low-
quality evidence only, which was attributable to a high risk of
methodological bias and imprecision in the point estimate. Fur-
ther research is likely to have an important impact on our confi-
dence in the estimate of effect and is likely to change the estimate.
Secondary outcomes that were reported in the included studies
were time to thrombolysis, ejection fraction and adverse effects.
There was high-quality evidence that time to thrombolysis is re-
duced when treatment is delivered pre-hospital compared with in
the hospital. Further research is unlikely to impact our confidence
in the estimate. We rated the evidence for the outcome of ejection
fraction as low quality, which we downgraded due to the risk of
methodological bias and imprecision (the confidence interval in-
cludes appreciable benefit and appreciable harm). Only low-qual-
ity evidence was available for all the adverse effect outcomes due
to high levels of imprecision, with the exception of the evidence
for bleeding complications, which we judged to be of moderate
quality.
Potential biases in the review process
We used Cochrane methodology to conduct a comprehensive
search to identify all the available trials in order to answer this
review question. Data for one potentially eligible study could not
be obtained as the authors did not provide the necessary data;
hence, we may have omitted additional evidence that could have
contributed to the results.
Agreements and disagreements with other
studies or reviews
Morrison 2000 is a systematic review andmeta-analysis of pre-hos-
pital versus in-hospital thrombolysis for acute myocardial infarc-
tion that assesses mortality. The study authors report a statistically
significant difference in all-cause hospital mortality in favour of
pre-hospital thrombolysis. Morrison 2000 included RCTs that as-
sessed the efficacy of thrombolysis for both STEMI andNSTEMI.
The current review specifically sought to investigate thromboly-
sis for STEMI as this type of therapy is not recommended for
NSTEMI (O’Connor 2010). Morrison 2000 found a mean time
difference of 60 minutes between pre-hospital and in-hospital
thrombolysis for acute myocardial infarction. Our results are con-
sistent with those of this previously published review.
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Implications for practice
Pre-hospital thrombolysis reduces time to thrombolytic treatment,
based on the results of three studies conducted in HICs. In set-
tings where it can be safely and correctly administered by trained
staff, pre-hospital thrombolysis may therefore be an appropriate
intervention. We were unable to determine whether pre-hospital
thrombolysis is superior to in-hospital thrombolysis with regard to
mortality, ejection fraction or adverse effects. Pre-hospital throm-
bolysis for STEMI has the potential to reduce the burden of dis-
ease in LMICs, especially in individuals who have limited access to
in-hospital thrombolysis or PCI (e.g. those living in rural areas).
Local policy makers and clinical directors should consider their
local health infrastructure and population distribution needs (ru-
ral compared with urban), emergency care system and the avail-
ability of thrombolytic therapy compared to surgical alternatives
(e.g. the availability of PCI). These considerations should be taken
into account when developing clinical guidelines for pre-hospital
thrombolysis. InWeaver 1993, pre-hospital thrombolysis was per-
formed by paramedics (emergency care professionals) with physi-
cian guidance, highlighting the advantage of a paramedic leadwith
physician teamwork as an alternative to a physician-led throm-
bolysis team, especially when considering physician availability in
LMICs.
Implications for research
The implications of these findings for research into STEMI are
less clear. Further research required may include studies that take
STEMI into consideration as opposed to AMI in general. We
found no RCTs that evaluated the efficacy of pre-hospital throm-
bolysis for STEMI in LMICs. Large high-quality multicentre
RCTs implemented in LMICs have the potential to develop those
countries’ health infrastructure and service delivery capacity. A
pragmatic approach to conducting these RCTs would be most ad-
vantageous in order to determine the efficacy and efficiency of
pre-hospital thrombolysis, especially taking into consideration the
health challenges of LMICs. Pragmatic RCTs (including feasibil-
ity studies) would contribute to the required infrastructure, health
system co-ordination, training models and policy development
necessary for the implementation and facilitation of pre-hospital
thrombolysis in LMICs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Castaigne 1989
Methods Two-phase study conducted in the Val de Marne district near Paris, France
Phase 1: Simulation and education over 1 year
Phase 2: Randomised trial conducted over 2 years
Participants Criteria for inclusion in trial:
1) Age < 75 years
2) Typical ischaemic chest pain for > 30 minutes and < 3 hours that did not respond to
nitrates
3) ST-segment elevation of 0.2 mV or more in at least 2 standard leads (posterior
infarction) or 3 precordial leads (anterior infarction)
4) No hypertension
5) No classic contraindication to thrombolytic therapy
Interventions Pre-hospital group: participants received nitrates and 30 U anisoylated plasminogen
streptokinase activator complex (APSAC) injected over > 4 minutes or placebo
In-hospital group: on arrival in the coronary care unit, the code was broken and, if
the individual had received placebo at home he/she received APSAC 30 U over > 4
minutes. The coronary care unit physician decided whether thrombolytic treatment was
appropriate
Outcomes Study endpoints:
1) Diagnostic accuracy, delay between phone call to emergency medical service and
arrival in coronary care unit for individuals included in or excluded from the trial
2) Delay between at-home and in-hospital injection for individuals having received
placebo at home
3) Events intervening during the pre-hospital phase
Notes Secondary reference (Dubois-Rande 1989) translated by Aurelie Jeandron
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of random sequence gener-
ation.
Allocation concealment (selection bias) High risk No description of allocation concealment.
Allocation codes were broken
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Mobile care unit physician was blinded to
the treatment; however, no description of
blinding provided. Furthermore, it is stated
that the code could be broken if the physi-
cian thought it necessary or if a cardiologist
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Castaigne 1989 (Continued)
was present when the ambulance reached
the individual’s home
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Code broken upon arrival at hospital and
therefore the assessor will have had knowl-
edge of treatment received.
Incomplete outcome data (attrition bias)
All outcomes
High risk Individuals did not appear to be assessed
according to intention to treat. Incomplete
data
Selective reporting (reporting bias) Low risk No indication of selective reporting.
Other bias Unclear risk Did not report a baseline characteristics ta-
ble - insufficient information to excluded
other possible biases
Schofer 1990
Methods Double-blind randomised controlled trial in Germany
Participants Criteria for inclusion in trial:
1) Severe chest pain typical of myocardial ischaemia lasting > 30 minutes
2) Arrival of the ambulance doctor within 4 hours after the onset of symptoms
3) ≥2 mm of ST-elevation in ≥2 ECG leads for inferior AMI and ≥ 3 mm of ST-
elevation in ≥2 precordial leads for anterior AMI
4) Age ≤ 70 years
5) No prior AMI
6) No contraindications against thrombolysis
Interventions Pre-hospital group: urokinase (2 million U intravenously) at home or placebo at hospital
In-hospital group: placebo at home or urokinase (2 million U intravenously) at hospital
Followed by 1000 U/hour of heparin at hospital
Outcomes Study end points:
1) Time intervals
2) Angiographic data and creatine kinase
3) Stress test before discharge
4) Complications
Notes Secondary reference (Mathey 1990) translated by Joerg Weber
Risk of bias
Bias Authors’ judgement Support for judgement
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Schofer 1990 (Continued)
Random sequence generation (selection
bias)
Unclear risk No description of random sequence gener-
ation. Authors only state participants were
randomly assigned to ampoule pairs
Allocation concealment (selection bias) Low risk Randomly assigned to the next in the series
of ampoule pairs
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Medac (Hamburg, Federal Republic of
Germany) prepared numbered pairs of am-
poules containing either urokinase in am-
poule A and placebo in ampoule B, or vice
versa
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk 1 individual was diagnosed with pul-
monary embolism and the data excluded.
Somemissing data for ejection fraction (see
figure 3)
Selective reporting (reporting bias) Low risk No indication of selective reporting.
Other bias Low risk No indication of other bias.
Weaver 1993
Methods Randomised controlled clinical trial conducted in the city of Seattle and the surrounding
King County from November 1988 to December 1991
Participants Criteria for inclusion in trial:
1) Individuals with suspected acute myocardial infarction, pain for 6 hours or less
2) aged ≤ 75 years, with no risk of bleeding (no history of stroke, recent bleeding or
uncontrolled systolic (less than 180 mmHg) or diastolic (less than 120 mmHg hyper-
tension)
3) 12-lead ECG was obtained and a physician reviewed the findings over the telephone
and made the final decision to randomise
Interventions Pre-hospital-initiated group: Aspirin 325 mg and alteplase 100 mg at home and no
placebo at hospital
Hospital-initiated group: no placebo at home and Aspirin 325 mg and alteplase 100 mg
at hospital
All participants received basicmedical care including oxygen, rhythmmonitoring devices
and intravenous access. Additionally, morphine sulphate was used for pain, lidocaine and
atropine for arrhythmias, and vasopressors and diuretics for treatment of hypotension
and pulmonary oedema (prescribed by the remote physician)
Sodium heparin administered to both groups on hospital arrival (5000 U bolus, followed
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Weaver 1993 (Continued)
by continuous intravenous infusion for at least 48 hours)
Outcomes Study endpoints:
1) Accuracy of diagnosis
2) Time to treatment
3) Complications
4) Ejection fraction
5) Infarct size
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of random sequence gener-
ation.
Allocation concealment (selection bias) Low risk Sealed treatment kits were identical in
terms of weight, balance and sound
Blinding of participants and personnel
(performance bias)
All outcomes
High risk For participants allocated to hospital-ini-
tiated treatment, no placebo was given in
the field but an active treatment kit was
available in the emergency department. Al-
teplase was infused in an open-label man-
ner
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk For assessment of infarct size and ventric-
ular function measures after hospital dis-
charge the core laboratory personnel were
blinded to the treatment assignment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It does not appear as if any participants
withdrew or were lost to follow up; this is
not reported in the text
Selective reporting (reporting bias) High risk Some complications are not reported in in-
tervention groups.
Other bias Low risk No indication of other bias.
ECG, electrocardiogram
AMI, acute myocardial infarction
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Armstrong 2010 Comparator percutaneous coronary intervention
Aufderheide 1992 Not randomised controlled trial. No thrombolytic therapy was administered in the field during this study
(feasibility study)
Bata 2009 Participants randomly assigned to receive primary percutaneous coronary intervention or fibrinolysis
BEPS Pilot study for GREAT trial - no randomised trial, no hospital thrombolysis intervention
Brugemann 1992 Data reported unclear - no mortality data (missing outcome data)
Cannon 2000 Not randomised controlled trial - used historical controls
Castaigne 1987 Outcome unclear - does not report number of participants in intervention or control groups
Castaigne 1990 Unclear mortality data, unclear time measurement and unclear ECG confirmation
Castle 2007 Not randomised controlled trial - retrospective descriptive analysis
Coccolini 1998 Not pure randomised controlled trial - consecutive participant allocation
Cuccia 1988 Thombolysis (IV streptokinase) vs standard therapy. Translated by Deirdre Beecher
Danchin 2004 French Nationwide Registry study
Doherty 2004 Not randomised controlled trial
Dussoix 2003 Compared pre-hospital thrombolysis to usual hospital care (in-hospital thrombolysis and mechanical inter-
vention)
EMIP Participants included those with non-ST segment elevated myocardial infarction. Authors contacted for
stratified (STEMI) data. Unable to provide missing data
Fokina 2008 Not randomised controlled trial. Translated by Marina Karanikolos
Goldstein 2005 Not randomised controlled trial
Grajek 2007 Not randomised controlled trial - discusses mitral regurgitation. Translated by Ela Gohil
GREAT Participation eligibility was not based on ECG findings (STEMI) but rather on strong clinical suspicion of
acute myocardial infarction by physician
Grijseels 1995 Not randomised controlled trial - retrospective control arm
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(Continued)
Herve 1988 Randomised controlled trial with no description of participant selection, no inclusion criteria, no indication
of age group or of how participants were diagnosed. Translated by Lynn Grignard
Hervé 1988a Randomised controlled trial comparing home thrombolysis to placebo. Translated by Lynn Grignard
Kasper 1999 Not randomised controlled trial. Translated by Nicole Martin
Kelly 2003 Not randomised controlled trial
Kelly 2010 Compared pre-hospital thrombolysis with half-dose pre-hospital thrombolysis and PCI
Khan 2009 Not randomised controlled trial - prospective cohort, no interventions
Koefoed-Nielse 2002 Quasi-experimental study (before and after trial)
Kudenchuk 1998 ECG study - outcomes focused on ECG abnormalities secondary to thrombolysis
Lamfers 1999 Not randomised controlled trial - retrospective review
Lamfers 2003 Not randomised controlled trial. Study of two different thrombolysis medications administered in the pre-
hospital setting
Lamfers 2004 Not randomised controlled trial
Linderer 1993 Not randomised controlled trial
Liu 2003 Randomised controlled trial comparing pre-hospital thrombolysis versus immediate angiography
Mathew 2003 Review of hospital data
McAleer 1992 Open allocation - not randomised controlled trial
McAleer 2006 Open allocation - not randomised controlled trial
McKendall 1991 Not randomised controlled trial
McNiell 1989 Some of the participants included in the trial were randomised for inclusion at the emergency department.
Study does not present all-cause mortality data, only cardiac-cause mortality data
McNiell 1991 Between 3 to 24 hours after administration of anistreplase, participants were randomised to receive either
intervention or conventional therapy
Millin 2008 Literature review
Morrison 2000 Systematic review including randomised controlled trials of pre-hospital vs in-hospital thrombolysis in AMI
with an outcome measure of all-cause hospital mortality. Selection criteria for participants were not similar
to those of the current systematic review
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(Continued)
Morrow 2002 Feasibility trial comparing pre-hospital thrombolysis to sequential in-hospital controls from 6 to 12 months
before
Rawles 1999 Randomised controlled trial reporting 5-year mortality
Risenfors 1991 Randomisation unclear - ECG criteria not used to include participants but recorded only after administration
and treatment
Roque 1995 Not randomised controlled trial. Translated by Joerg Weber
Rosell-Ortiz 2008 Prospective database cohort
Rosenberg 2002 Open-label pilot study administering a first bolus of reteplase before emergency department arrival and the
second bolus after emergency department arrival
Roth 1990 Not randomised controlled trial - used alternative monthly allocation
Rozenman 1994 Not randomised controlled trial - alternative allocation
Rozenman 1995 Not randomised controlled trial
Ruda 2009 Participants with spontaneous reperfusion were randomised to be treated with emergency coronary angiog-
raphy and, in case of stenosis >50%, balloon angioplasty or conservative treatment. Translated by Marina
Karanikolos
Smalling 2007 Randomised controlled trial comparing pre-hospital thrombolysis with PCI
Smith 2011 Prospective data collection for all individuals admitted to Chesterfield Royal Hospital who received throm-
bolysis for a presumed myocardial infarction over a 12-month period
Stewart 1993 Not randomised controlled trial
Svensson 2003 Feasibility study, no randomisation
Tatu-Chitoiu 2002 Pre-hospital accelerated streptokinase combined with enoxaparin and in-hospital accelerated streptokinase
combined with enoxaparin compared to in-hospital standard streptokinase with heparin
Topol 1986 Not randomised controlled trial
Trent 1995 Secondary analysis of GREAT data
Walletin 2003 Pateints with STEMI in the pre-hospital setting were randomised to receive tenecteplase and either (1)
intravenous bolus of 30 mg enoxaparin followed by 1 mg/kg subcutaneously twice daily for a maximum of
7 days or (2) weight-adjusted unfractionated heparin for 48 hours
Weaver 1994 Not randomised controlled trial
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(Continued)
White 1990 Participants were randomised to receive intravenous streptokinase plus rt-PA placebo over 3 hours or strep-
tokinase placebo infused over 30 minutes plus rt-PA infusion over 3 hours
Woollard 2005 Randomised to telemetry and conventional treatment - no active thrombolysis
Zeymer 2009 Report on the data of the German Prehospital Myocardial Infarction Registry
AMI, acute myocardial infarction
ECG, electrocardiogram
IV, intravenously
PCI, percutaneous coronary intervention
rt-PA, recombinant tissue plasminogen activator
STEMI, ST-elevation myocardial infarction
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D A T A A N D A N A L Y S E S
Comparison 1. Pre-hospital versus in-hospital thrombolysis mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All cause hospital mortality 3 538 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.37, 1.41]
Comparison 2. Pre-hospital versus in-hospital thrombolysis morbidity
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to thrombolytic treatment 2 438 Mean Difference (IV, Random, 95% CI) -37.95 [-61.12, -14.
77]
2 Acute myocardial infarction
functional outcomes
2 416 Mean Difference (IV, Fixed, 95% CI) -1.18 [-3.50, 1.13]
2.1 Ejection Fraction
[Percentage]
2 416 Mean Difference (IV, Fixed, 95% CI) -1.18 [-3.50, 1.13]
3 Adverse effects 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Ventricullar Fribrillation 2 178 Risk Ratio (M-H, Fixed, 95% CI) 2.73 [0.68, 10.86]
3.2 Hypotension 2 178 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.47, 3.49]
3.3 Bleeding complications 2 438 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.41, 1.92]
3.4 Allergic Reaction 1 100 Risk Ratio (M-H, Fixed, 95% CI) 3.79 [0.19, 77.03]
3.5 Intubation 1 78 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.06, 14.65]
3.6 Cardiac Massage 1 78 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.55]
3.7 Ventricular tachycardia 1 78 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.48, 3.31]
3.8 Wrong Diagnosis 1 78 Risk Ratio (M-H, Fixed, 95% CI) 2.85 [0.12, 67.97]
3.9 Pulmonary Congestion 1 78 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.40, 2.28]
3.10 Post-infact Angina 1 78 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.14, 6.41]
3.11 Bradycardia 1 78 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.15, 2.22]
3.12 Reinfaction 1 78 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.22, 2.62]
3.13 Percutaneous
transluminal coronary
angioplasty
1 78 Risk Ratio (M-H, Fixed, 95% CI) 3.8 [0.44, 32.49]
3.14 Coronary Artery Bypass
Graft
1 78 Risk Ratio (M-H, Fixed, 95% CI) 2.85 [0.12, 67.97]
3.15 Stroke 1 360 Risk Ratio (M-H, Fixed, 95% CI) 2.11 [0.39, 11.40]
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Comparison 3. Pre-hospital versus in-hospital thrombolysis: Mortality sensitivity analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All cause hospital mortality 2 438 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.32, 1.41]
Analysis 1.1. Comparison 1 Pre-hospital versus in-hospital thrombolysis mortality, Outcome 1 All cause
hospital mortality.
Review: Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction
Comparison: 1 Pre-hospital versus in-hospital thrombolysis mortality
Outcome: 1 All cause hospital mortality
Study or subgroup
Pre-hospital
thromboly-
sis
In-hospital
thromboly-
sis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Castaigne 1989 3/50 3/50 15.3 % 1.00 [ 0.21, 4.72 ]
Schofer 1990 1/40 2/38 10.4 % 0.48 [ 0.04, 5.03 ]
Weaver 1993 10/175 15/185 74.3 % 0.70 [ 0.33, 1.53 ]
Total (95% CI) 265 273 100.0 % 0.73 [ 0.37, 1.41 ]
Total events: 14 (Pre-hospital thrombolysis), 20 (In-hospital thrombolysis)
Heterogeneity: Chi2 = 0.29, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours pre-hospital Favours in-hospital
32Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Pre-hospital versus in-hospital thrombolysis morbidity, Outcome 1 Time to
thrombolytic treatment.
Review: Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction
Comparison: 2 Pre-hospital versus in-hospital thrombolysis morbidity
Outcome: 1 Time to thrombolytic treatment
Study or subgroup
Pre-hospital
thromboly-
sis
In-hospital
thromboly-
sis
Mean
Difference Weight
Mean
Difference
N Mean(SD)[Minutes] N Mean(SD)[Minutes] IV,Random,95% CI IV,Random,95% CI
Schofer 1990 40 85 (51) 38 137 (50) 41.4 % -52.00 [ -74.42, -29.58 ]
Weaver 1993 175 92 (58) 185 120 (49) 58.6 % -28.00 [ -39.12, -16.88 ]
Total (95% CI) 215 223 100.0 % -37.95 [ -61.12, -14.77 ]
Heterogeneity: Tau2 = 206.49; Chi2 = 3.53, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 3.21 (P = 0.0013)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours pre-hospital Favours in-hospital
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Analysis 2.2. Comparison 2 Pre-hospital versus in-hospital thrombolysis morbidity, Outcome 2 Acute
myocardial infarction functional outcomes.
Review: Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction
Comparison: 2 Pre-hospital versus in-hospital thrombolysis morbidity
Outcome: 2 Acute myocardial infarction functional outcomes
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ejection Fraction [Percentage]
Schofer 1990 28 50.6 (10) 28 53 (14) 13.2 % -2.40 [ -8.77, 3.97 ]
Weaver 1993 175 53 (12) 185 54 (12) 86.8 % -1.00 [ -3.48, 1.48 ]
Total (95% CI) 203 213 100.0 % -1.18 [ -3.50, 1.13 ]
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours experimental Favours control
34Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Pre-hospital versus in-hospital thrombolysis morbidity, Outcome 3 Adverse
effects.
Review: Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction
Comparison: 2 Pre-hospital versus in-hospital thrombolysis morbidity
Outcome: 3 Adverse effects
Study or subgroup
Pre-hospital
thromboly-
sis
In-hospital
thromboly-
sis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ventricullar Fribrillation
Castaigne 1989 1/57 0/43 21.7 % 2.28 [ 0.09, 54.54 ]
Schofer 1990 6/40 2/38 78.3 % 2.85 [ 0.61, 13.26 ]
Subtotal (95% CI) 97 81 100.0 % 2.73 [ 0.68, 10.86 ]
Total events: 7 (Pre-hospital thrombolysis), 2 (In-hospital thrombolysis)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
2 Hypotension
Castaigne 1989 5/57 2/43 35.7 % 1.89 [ 0.38, 9.26 ]
Schofer 1990 4/40 4/38 64.3 % 0.95 [ 0.26, 3.53 ]
Subtotal (95% CI) 97 81 100.0 % 1.28 [ 0.47, 3.49 ]
Total events: 9 (Pre-hospital thrombolysis), 6 (In-hospital thrombolysis)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
3 Bleeding complications
Schofer 1990 1/40 2/38 16.1 % 0.48 [ 0.04, 5.03 ]
Weaver 1993 10/175 11/185 83.9 % 0.96 [ 0.42, 2.21 ]
Subtotal (95% CI) 215 223 100.0 % 0.88 [ 0.41, 1.92 ]
Total events: 11 (Pre-hospital thrombolysis), 13 (In-hospital thrombolysis)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
4 Allergic Reaction
Castaigne 1989 2/57 0/43 100.0 % 3.79 [ 0.19, 77.03 ]
Subtotal (95% CI) 57 43 100.0 % 3.79 [ 0.19, 77.03 ]
Total events: 2 (Pre-hospital thrombolysis), 0 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
5 Intubation
Schofer 1990 1/40 1/38 100.0 % 0.95 [ 0.06, 14.65 ]
Subtotal (95% CI) 40 38 100.0 % 0.95 [ 0.06, 14.65 ]
Total events: 1 (Pre-hospital thrombolysis), 1 (In-hospital thrombolysis)
0.005 0.1 1 10 200
Favours pre-hospital Favours in-hospital
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(. . . Continued)
Study or subgroup
Pre-hospital
thromboly-
sis
In-hospital
thromboly-
sis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
6 Cardiac Massage
Schofer 1990 0/40 1/38 100.0 % 0.32 [ 0.01, 7.55 ]
Subtotal (95% CI) 40 38 100.0 % 0.32 [ 0.01, 7.55 ]
Total events: 0 (Pre-hospital thrombolysis), 1 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
7 Ventricular tachycardia
Schofer 1990 8/40 6/38 100.0 % 1.27 [ 0.48, 3.31 ]
Subtotal (95% CI) 40 38 100.0 % 1.27 [ 0.48, 3.31 ]
Total events: 8 (Pre-hospital thrombolysis), 6 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
8 Wrong Diagnosis
Schofer 1990 1/40 0/38 100.0 % 2.85 [ 0.12, 67.97 ]
Subtotal (95% CI) 40 38 100.0 % 2.85 [ 0.12, 67.97 ]
Total events: 1 (Pre-hospital thrombolysis), 0 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
9 Pulmonary Congestion
Schofer 1990 8/40 8/38 100.0 % 0.95 [ 0.40, 2.28 ]
Subtotal (95% CI) 40 38 100.0 % 0.95 [ 0.40, 2.28 ]
Total events: 8 (Pre-hospital thrombolysis), 8 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
10 Post-infact Angina
Schofer 1990 2/40 2/38 100.0 % 0.95 [ 0.14, 6.41 ]
Subtotal (95% CI) 40 38 100.0 % 0.95 [ 0.14, 6.41 ]
Total events: 2 (Pre-hospital thrombolysis), 2 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
11 Bradycardia
Schofer 1990 3/40 5/38 100.0 % 0.57 [ 0.15, 2.22 ]
Subtotal (95% CI) 40 38 100.0 % 0.57 [ 0.15, 2.22 ]
Total events: 3 (Pre-hospital thrombolysis), 5 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
12 Reinfaction
Schofer 1990 4/40 5/38 100.0 % 0.76 [ 0.22, 2.62 ]
0.005 0.1 1 10 200
Favours pre-hospital Favours in-hospital
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Study or subgroup
Pre-hospital
thromboly-
sis
In-hospital
thromboly-
sis Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 40 38 100.0 % 0.76 [ 0.22, 2.62 ]
Total events: 4 (Pre-hospital thrombolysis), 5 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
13 Percutaneous transluminal coronary angioplasty
Schofer 1990 4/40 1/38 100.0 % 3.80 [ 0.44, 32.49 ]
Subtotal (95% CI) 40 38 100.0 % 3.80 [ 0.44, 32.49 ]
Total events: 4 (Pre-hospital thrombolysis), 1 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
14 Coronary Artery Bypass Graft
Schofer 1990 1/40 0/38 100.0 % 2.85 [ 0.12, 67.97 ]
Subtotal (95% CI) 40 38 100.0 % 2.85 [ 0.12, 67.97 ]
Total events: 1 (Pre-hospital thrombolysis), 0 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
15 Stroke
Weaver 1993 4/175 2/185 100.0 % 2.11 [ 0.39, 11.40 ]
Subtotal (95% CI) 175 185 100.0 % 2.11 [ 0.39, 11.40 ]
Total events: 4 (Pre-hospital thrombolysis), 2 (In-hospital thrombolysis)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Chi2 = 7.28, df = 14 (P = 0.92), I2 =0.0%
0.005 0.1 1 10 200
Favours pre-hospital Favours in-hospital
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Analysis 3.1. Comparison 3 Pre-hospital versus in-hospital thrombolysis: Mortality sensitivity analysis,
Outcome 1 All cause hospital mortality.
Review: Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction
Comparison: 3 Pre-hospital versus in-hospital thrombolysis: Mortality sensitivity analysis
Outcome: 1 All cause hospital mortality
Study or subgroup Pre-hospital In-hospital Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Schofer 1990 1/40 2/38 12.3 % 0.48 [ 0.04, 5.03 ]
Weaver 1993 10/175 15/185 87.7 % 0.70 [ 0.33, 1.53 ]
Total (95% CI) 215 223 100.0 % 0.68 [ 0.32, 1.41 ]
Total events: 11 (Pre-hospital), 17 (In-hospital)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [pre-hospital] Favours [in-hospital]
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Appendix 1. Appendix
CENTRAL
#1 MeSH descriptor: [Myocardial Infarction] explode all trees
#2 “myocardial infarct*”
#3 “heart infarct*”
#4 ami
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Fibrinolytic Agents] this term only
#7 MeSH descriptor: [Thrombolytic Therapy] this term only
#8 thromboly*
#9 alteplase
#10 reteplase
#11 streptokinase
#12 tenecteplase
#13 urokinase
#14 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 #5 and #14
#16 MeSH descriptor: [Hospitals] explode all trees
#17 hospital*
#18 prehospital*
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#19 pre-hospital*
#20 #16 or #17 or #18 or #19
#21 #15 and #20
1. exp Myocardial Infarction/
2. myocardial infarct$.tw.
3. heart infarct$.tw.
4. ami.tw.
5. 1 or 2 or 3 or 4
6. Fibrinolytic Agents/
7. Thrombolytic Therapy/
8. thromboly$.tw.
9. alteplase.tw.
10. reteplase.tw.
11. streptokinase.tw.
12. tenecteplase.tw.
13. urokinase.tw.
14. or/6-13
15. 5 and 14
16. exp Hospitals/
17. hospital$.tw.
18. prehospital$.tw.
19. pre-hospital$.tw.
20. 16 or 17 or 18 or 19
21. 15 and 20
22. randomized controlled trial.pt.
23. controlled clinical trial.pt.
24. randomized.ab.
25. placebo.ab.
26. clinical trials as topic.sh.
27. randomly.ab.
28. trial.ti.
29. 22 or 23 or 24 or 25 or 26 or 27 or 28
30. exp animals/ not humans.sh.
31. 29 not 30
32. 21 and 31
MEDLINE OVID
1. exp Myocardial Infarction/
2. myocardial infarct$.tw.
3. heart infarct$.tw.
4. ami.tw.
5. 1 or 2 or 3 or 4
6. Fibrinolytic Agents/
7. Thrombolytic Therapy/
8. thromboly$.tw.
9. alteplase.tw.
10. reteplase.tw.
11. streptokinase.tw.
12. tenecteplase.tw.
13. urokinase.tw.
14. or/6-13
15. 5 and 14
16. exp Hospitals/
17. hospital$.tw.
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18. prehospital$.tw.
19. pre-hospital$.tw.
20. 16 or 17 or 18 or 19
21. 15 and 20
22. randomized controlled trial.pt.
23. controlled clinical trial.pt.
24. randomized.ab.
25. placebo.ab.
26. clinical trials as topic.sh.
27. randomly.ab.
28. trial.ti.
29. 22 or 23 or 24 or 25 or 26 or 27 or 28
30. exp animals/ not humans.sh.
31. 29 not 30
32. 21 and 31
EMBASE OVID
1. exp heart infarction/
2. myocardial infarct$.tw.
3. heart infarct$.tw.
4. ami.tw.
5. or/1-4
6. fibrinolytic agent/
7. fibrinolytic therapy/
8. thromboly$.tw.
9. alteplase.tw.
10. reteplase.tw.
11. streptokinase.tw.
12. tenecteplase.tw.
13. urokinase.tw.
14. or/6-13
15. 5 and 14
16. exp hospital/
17. hospital$.tw.
18. prehospital$.tw.
19. pre-hospital$.tw.
20. or/16-19
21. 15 and 20
22. random$.tw.
23. factorial$.tw.
24. crossover$.tw.
25. cross over$.tw.
26. cross-over$.tw.
27. placebo$.tw.
28. (doubl$ adj blind$).tw.
29. (singl$ adj blind$).tw.
30. assign$.tw.
31. allocat$.tw.
32. volunteer$.tw.
33. crossover procedure/
34. double blind procedure/
35. randomized controlled trial/
36. single blind procedure/
37. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
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38. (animal/ or nonhuman/) not human/
39. 37 not 38
40. 21 and 39
41. limit 40 to embase
Web of Science
#19 #18 AND #17
#18 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
#17 #16 AND #12 AND #4
#16 #15 OR #14 OR #13
#15 TS=pre-hospital*
#14 TS=prehospital*
#13 TS=hospital*
#12 #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5
#11 TS=urokinase
#10 TS=tenecteplase
#9 TS=streptokinase
#8 TS=reteplase
#7 TS=alteplase
#6 TS=thromboly*
#5 TS=fibrinolyt*
#4 #3 OR #2 OR #1
#3 TS=ami
#2 TS=(heart SAME infarct*)
#1 TS=(myocardial SAME infarct*)
CINAHL
S21 S20 Limiters - Exclude MEDLINE records
S20 S17 and S18 and S19
S19 S13 or S14 or S15 or S16
S18 S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12
S17 S1 or S2 or S3 or S4
S16 AB pre-hospital* or TI pre-hospital*
S15 AB prehospital* or TI prehospital*
S14 AB hospital* or TI hospital*
S13 (MH “Hospitals+”)
S12 AB urokinase or TI urokinase
S11 AB tenecteplase or TI tenecteplase
S10 AB streptokinase or TI streptokinase
S9 AB reteplase or TI reteplase
S8 AB alteplase OR TI alteplase
S7 AB thromboly* or TI thromboly*
S6 (MH “Thrombolytic Therapy”)
S5 (MH “Fibrinolytic Agents”)
S4 AB ami or TI ami
S3 AB “heart infarct*” or TI “heart infarct*”
S2 AB “myocard* infarct*” or TI “myocard* infarct*”
S1 (MH “Myocardial Infarction+”)
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